RecruitingNCT05046444

Solving Riddles Through Sequencing

Testing the Diagnostic Supremacy of Sequencing-only Approaches in Hematologic Malignancies: an Observational Trial


Sponsor

Munich Leukemia Laboratory

Enrollment

100 participants

Start Date

Jan 19, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients. This continuous evolution proceeded in parallel to seminal discoveries in basic science such as FISH, PCR and NGS. So far, the current WHO classification serves as reference to diagnostic decision making and is largely based on 5 diagnostic pillars: cytomorphology of peripheral blood and/or bone marrow smears, histology and immunohistochemistry of bone marrow trephine biopsies or lymph nodes, immunophenotyping, chromosome banding analysis supplemented by FISH analysis, molecular genetics including PCR and targeted panel sequencing via NGS. This leads to a swift diagnosis in 90 % of all cases. The leftover 10 % remain a challenge for hematopathologists and clinicians alike and are resolved through interdisciplinary teams in the context of specialized boards. With the advent of high throughput sequencing (mainly WGS and WTS) the possibility of a comprehensive and detailed portrait of the genetic alterations - specifically in challenging cases - has become a realistic alternative to classical methods. In SIRIUS the investigators will prospectively challenge this hypothesis to address the question of how often a better or final diagnosis can be delivered by WGS and/or WTS and if unclear cases can be efficiently resolved.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study uses advanced genetic sequencing (like reading the DNA of cancer cells) to solve difficult or puzzling blood cancer cases where a clear diagnosis has not been established through standard testing. It aims to give doctors more information to improve treatment decisions. **You may be eligible if...** - You are 18 or older and have a suspected blood disorder or blood cancer - Your diagnosis is unclear, your disease is behaving unusually, or standard tests have been unsatisfactory - You have provided informed consent - Your sample has at least 20% cancer cells **You may NOT be eligible if...** - Your tissue sample is of poor quality or fails initial quality checks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTNext Generation Sequencing

NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods


Locations(1)

MLL Munich Leukemia Laboratory

Munich, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05046444


Related Trials